|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093456 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-06 16:34:01 |
|
注册时间: Date of Registration: |
2024-12-05 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
急性呼吸窘迫综合征的流行病学特征及预测体系研究 |
|
Public title: |
Epidemiological characteristics and prediction system of acute respiratory distress syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
急性呼吸窘迫综合征的流行病学特征及预测体系研究 |
|
Scientific title: |
Epidemiological characteristics and prediction system of acute respiratory distress syndrome |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄絮 |
研究负责人: |
黄絮 |
|
Applicant: |
Huang Xu |
Study leader: |
Huang Xu |
|
申请注册联系人电话: Applicant telephone: |
+86 13641345816 |
研究负责人电话:
Study leader's |
+86 10 84205039 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huangxu1122@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
huangxu1122@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区樱花园东街2号 |
研究负责人通讯地址: |
朝阳区樱花东街2号 |
|
Applicant address: |
NO.2 yinghuayuandong street, Beijing |
Study leader's address: |
No.2 , Yinghua East Street, Chaoyang Dist. Beijing ,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中日友好医院 |
||
|
Applicant's institution: |
China-Japan Friendship Hospital |
||
|
研究负责人所在单位: |
中日友好医院 |
||
|
Affiliation of the Leader: |
China-Japan Friendship Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-KY-196 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中日友好医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of China-Japan Friendship Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-09-11 00:00:00 | ||
|
伦理委员会联系人: |
闫旭 |
||
|
Contact Name of the ethic committee: |
Yan Xu |
||
|
伦理委员会联系地址: |
朝阳区樱花东街2号 |
||
|
Contact Address of the ethic committee: |
No.2 , Yinghua East Street, Chaoyang Dist. Beijing ,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 84206250 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
235166769@qq.com |
|
研究实施负责(组长)单位: |
中日友好医院 |
||||||||||||||||||||||
|
Primary sponsor: |
China-Japan Friendship Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
朝阳区樱花东街2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.2 , Yinghua East Street, Chaoyang Dist. Beijing ,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中日友好医院高水平医院临床业务费专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
National High Level Hospital Clinical Research Funding |
||||||||||||||||||||||
|
研究疾病: |
急性呼吸窘迫综合征 |
||||||||||||||||||||||
|
Target disease: |
Acute Respiratory Distress Syndrome |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本课题拟采用多中心前瞻性真实世界研究的方法,对RICU内ARDS患者的发病率、分级、高危因素、呼吸支持策略、住院病死率、3个月病死率、6个月病死率、1年病死率和生活质量、肺功能和肢体功能恢复情况、认知功能、返岗等情况进行摸底性研究,通过收集1000例患者,建立中国ARDS相关的临床数据库,为ARDS患者规范化诊治技术的推广及进一步的临床干预研究提供基础数据和思路。同时在中日医院和湘雅医院建立ARDS生物样本库,实现临床数据和样本资源的融合,并利用大数据和AI技术,建立结核临床数据和生物样本的ARDS生存和并发症预测模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study plans to adopt a multi-center prospective real-world research method to investigate the incidence, classification, risk factors, respiratory support strategies, in-hospital mortality, 3-month mortality, 6-month mortality, 1-year mortality, quality of life, lung function and limb function recovery, cognitive function, return-to-work status, and other aspects of ARDS patients in the RICU. By collecting data from 1000 patients, a clinical database related to ARDS in China will be established, providing fundamental data and insights for the standardized diagnosis and treatment of ARDS patients and further clinical intervention research. Simultaneously, ARDS biobanks will be established at Zhongda Hospital and Xiangya Hospital to integrate clinical data and sample resources. By leveraging big data and AI technology, a predictive model for ARDS survival and complications based on clinical data and biological samples will be developed. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
入 ICU 当时或入 ICU 期间诊断为 ARDS |
||||||||||||||||||||||
|
Inclusion criteria |
Diagnosed with ARDS at or during admission to the ICU |
||||||||||||||||||||||
|
排除标准: |
1.年龄小于18岁; 2.患者或家属拒绝参加该项注册研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Under 18 years of age; 2.Patients or family members refused to participate in the enrollment study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-08-01 00:00:00至 To 2025-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-09-23 00:00:00 至 To 2025-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本项目数据建立的数据库和数据库平台所有权属于全体参研单位,具体保存在中日友好医院。成立数据库使用学术委员会(成员20名),数据库使用规程如下1.本研究数据库向所有参研单位开放。使用数据库之前需要向学术委员会提交数据使用申请及研究方案,说明使用原因和用途,需经过学术委员会成员15名以上通过才可使用该数据库。2.所有数据必须保密,使用前须签署保密协议,不得外传。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The ownership of the database and database platform established for this project belongs to all participating research units, and it is specifically stored at the China-Japan Friendship Hospital. A Database Usage Academic Committee has been established (consisting of 20 members), and the database usage regulations are as follows:The research database is open to all participating units. Before using the database, a data usage application and research proposal must be submitted to the academic committee, explaining the reasons and purposes for usage. Approval from more than 15 members of the academic committee is required before the database can be accessed.All data must be kept confidential, and a confidentiality agreement must be signed before use. The data may not be disclosed externally. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:病例记录表; 数据管理:电子数据采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: CRF Data Management: Electronic Data Collection and Management System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |